Nitrated α–Synuclein Immunity Accelerates Degeneration of Nigral Dopaminergic Neurons
暂无分享,去创建一个
H. Gendelman | E. Benner | S. Przedborski | P. Ciborowski | R. Mosley | Rebecca Banerjee | Simon Sherman | Ashley D. Reynolds | V. Pisarev | V. Tsiperson | Craig Nemachek
[1] Vladimir N. Uversky,et al. Neuropathology, biochemistry, and biophysics of α‐synuclein aggregation , 2007 .
[2] G. Miller,et al. Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice , 2007, Proceedings of the National Academy of Sciences.
[3] Lynette M. Smith,et al. Investigating the human immunodeficiency virus type 1-infected monocyte-derived macrophage secretome. , 2007, Virology.
[4] Howard E. Gendelman,et al. Cytoskeletal Protein Transformation in HIV-1-Infected Macrophage Giant Cells1 , 2007, The Journal of Immunology.
[5] Julia Thom Oxford,et al. Calpain-Cleavage of α-Synuclein : Connecting Proteolytic Processing to Disease-Linked Aggregation , 2007 .
[6] Howard E. Gendelman,et al. HIV-1 infected monocyte-derived macrophages affect the human brain microvascular endothelial cell proteome: New insights into blood–brain barrier dysfunction for HIV-1-associated dementia , 2007, Journal of Neuroimmunology.
[7] H. Gendelman,et al. Genomic and proteomic microglial profiling: pathways for neuroprotective inflammatory responses following nerve fragment clearance and activation , 2007, Journal of neurochemistry.
[8] Richard D. Smith,et al. Endogenously nitrated proteins in mouse brain: links to neurodegenerative disease. , 2006, Biochemistry.
[9] Morten Nielsen,et al. A Community Resource Benchmarking Predictions of Peptide Binding to MHC-I Molecules , 2006, PLoS Comput. Biol..
[10] A. Sidhu,et al. An Inflammatory Pathomechanism for Parkinsons Disease , 2006 .
[11] R. Dringen. Oxidative and antioxidative potential of brain microglial cells. , 2005, Antioxidants & redox signaling.
[12] James R. Anderson,et al. Proteomic fingerprints distinguish microglia, bone marrow, and spleen macrophage populations , 2005, Glia.
[13] Makoto Hashimoto,et al. Effects of α-Synuclein Immunization in a Mouse Model of Parkinson’s Disease , 2005, Neuron.
[14] L. Moran,et al. Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition , 2005, Journal of Neuroinflammation.
[15] H. Ohmori,et al. Immunogenicity of an inflammation-associated product, tyrosine nitrated self-proteins. , 2005, Autoimmunity reviews.
[16] Belinda Wilson,et al. Aggregated α‐synuclein activates microglia: a process leading to disease progression in Parkinson's disease , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[17] Y. Lyubchenko,et al. Effects of nitration on the structure and aggregation of α-synuclein , 2005 .
[18] L. Schmued,et al. Fluoro-Jade C results in ultra high resolution and contrast labeling of degenerating neurons , 2005, Brain Research.
[19] H. Gendelman,et al. Diminished matrix metalloproteinase 9 secretion in human immunodeficiency virus-infected mononuclear phagocytes: modulation of innate immunity and implications for neurological disease , 2004, Journal of Neuroimmunology.
[20] D. Lynch,et al. Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation. , 2004, The Journal of biological chemistry.
[21] Philippe Amouyel,et al. α-synuclein locus duplication as a cause of familial Parkinson's disease , 2004, The Lancet.
[22] Thomas Klockgether,et al. Parkinson’s disease: clinical aspects , 2004, Cell and Tissue Research.
[23] H. Gendelman,et al. Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[24] A. Sidhu,et al. Does α‐synuclein modulate dopaminergic synaptic content and tone at the synapse? , 2004 .
[25] J. Hoenicka,et al. The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia , 2004, Annals of neurology.
[26] Andre Parent,et al. Presence of reactive microglia in monkey substantia nigra years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine administration , 2003, Annals of neurology.
[27] Janel O. Johnson,et al. α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.
[28] Jie Li,et al. The Association of α-Synuclein with Membranes Affects Bilayer Structure, Stability, and Fibril Formation* , 2003, Journal of Biological Chemistry.
[29] M. Cookson,et al. α‐Synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[30] Makoto Sawada,et al. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains , 2003, Acta Neuropathologica.
[31] W. Dauer,et al. Parkinson's Disease Mechanisms and Models , 2003, Neuron.
[32] H. Reichmann,et al. HLA Typing and Parkinson’s Disease , 2003, European Neurology.
[33] H. Birnboim,et al. Cutting Edge: MHC Class II-Restricted Peptides Containing the Inflammation-Associated Marker 3-Nitrotyrosine Evade Central Tolerance and Elicit a Robust Cell-Mediated Immune Response 1 , 2003, The Journal of Immunology.
[34] B. Dubois,et al. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization , 2003, Neurology.
[35] Pingping Guan,et al. MHCPred: a server for quantitative prediction of peptide-MHC binding , 2003, Nucleic Acids Res..
[36] Min Zhu,et al. Lipid Binding Inhibits α-Synuclein Fibril Formation* , 2003, The Journal of Biological Chemistry.
[37] V. Uversky,et al. Nitration inhibits fibrillation of human α‐synuclein in vitro by formation of soluble oligomers , 2003 .
[38] M. Vila,et al. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[39] C. Holmes,et al. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report , 2003, Nature Medicine.
[40] H. Ischiropoulos,et al. Oxidative stress and nitration in neurodegeneration: cause, effect, or association? , 2003, The Journal of clinical investigation.
[41] J. Trojanowski,et al. Phosphorylated α-Synuclein Is Ubiquitinated in α-Synucleinopathy Lesions* , 2002, The Journal of Biological Chemistry.
[42] G. Miller,et al. Detection of Behavioral Impairments Correlated to Neurochemical Deficits in Mice Treated with Moderate Doses of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine , 2002, Experimental Neurology.
[43] A. Manning-Boğ,et al. Environmental factors in Parkinson's disease. , 2002, Neurotoxicology.
[44] M. Schwartz,et al. Myelin specific Th1 cells are necessary for post-traumatic protective autoimmunity , 2002, Journal of Neuroimmunology.
[45] P. Lansbury,et al. Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. , 2002, Biochemistry.
[46] Dong-Kug Choi,et al. Blockade of Microglial Activation Is Neuroprotective in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson Disease , 2002, The Journal of Neuroscience.
[47] E. Check. Nerve inflammation halts trial for Alzheimer's drug , 2002, Nature.
[48] John Q. Trojanowski,et al. Induction of α-Synuclein Aggregation by Intracellular Nitrative Insult , 2001, The Journal of Neuroscience.
[49] Y. Itoyama,et al. Increase in peripheral CD4 bright+ CD8 dull+ T cells in Parkinson disease. , 2001, Archives of neurology.
[50] H. Weiner. Oral tolerance: immune mechanisms and the generation of Th3-type TGF-beta-secreting regulatory cells. , 2001, Microbes and infection.
[51] H. Doyle,et al. Post-translational protein modifications in antigen recognition and autoimmunity. , 2001, Trends in immunology.
[52] H. Burkhardt,et al. Chicken and egg in autoimmunity and joint inflammation. , 2001, Trends in immunology.
[53] V. Uversky,et al. Evidence for a Partially Folded Intermediate in α-Synuclein Fibril Formation* , 2001, The Journal of Biological Chemistry.
[54] D. Eliezer,et al. Conformational properties of alpha-synuclein in its free and lipid-associated states. , 2001, Journal of molecular biology.
[55] G. Petzinger,et al. The parkinsonian toxin 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP): a technical review of its utility and safety , 2001, Journal of neurochemistry.
[56] Virginia M. Y. Lee,et al. Oxidative post‐translational modifications of α‐synuclein in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) mouse model of Parkinson's disease , 2001, Journal of neurochemistry.
[57] V. Uversky,et al. Why are “natively unfolded” proteins unstructured under physiologic conditions? , 2000, Proteins.
[58] J. Trojanowski,et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. , 2000, Science.
[59] R. Motter,et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease , 2000, Nature Medicine.
[60] J. Streilein,et al. Systemic Immune Deviation in the Brain That Does Not Depend on the Integrity of the Blood-Brain Barrier1 , 2000, The Journal of Immunology.
[61] M. Hur,et al. Expression Patterns of α-Synuclein in Human Hematopoietic Cells and in Drosophila at Different Developmental Stages , 2000 .
[62] Ted M. Dawson,et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease , 1999, Nature Medicine.
[63] E. Daikhin,et al. Factors determining the selectivity of protein tyrosine nitration. , 1999, Archives of biochemistry and biophysics.
[64] J. Langston,et al. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine exposure , 1999, Annals of neurology.
[65] R. Motter,et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.
[66] J. Piette,et al. The key role of nucleosomes in lupus. , 1999, Arthritis and rheumatism.
[67] D. Neill,et al. Aggregates from mutant and wild‐type α‐synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of β‐sheet and amyloid‐like filaments , 1998, FEBS letters.
[68] Peter T. Lansbury,et al. Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease , 1998, Nature Medicine.
[69] D. Mevorach,et al. Systemic Exposure to Irradiated Apoptotic Cells Induces Autoantibody Production , 1998, The Journal of experimental medicine.
[70] P. Anderson,et al. Posttranslational protein modifications, apoptosis, and the bypass of tolerance to autoantigens. , 1998, Arthritis and rheumatism.
[71] Robert L. Nussbaum,et al. Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .
[72] A. Rosen,et al. Scleroderma Autoantigens Are Uniquely Fragmented by Metal-catalyzed Oxidation Reactions: Implications for Pathogenesis , 1997, The Journal of experimental medicine.
[73] P. Lansbury,et al. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. , 1996, Biochemistry.
[74] J. Streilein,et al. Intraocular injection of class II-restricted peptide induces an unexpected population of CD8 regulatory cells. , 1996, Journal of immunology.
[75] A. Członkowska,et al. Humoral response to hsp 65 and hsp 70 in cerebrospinal fluid in Parkinson's disease , 1996, Journal of the Neurological Sciences.
[76] R. Burke,et al. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1995, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.
[77] S. Appel,et al. Experimental autoimmune nigral damage in guinea pigs , 1995, Journal of Neuroimmunology.
[78] H. Weiner. Oral tolerance. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[79] V. Kostulas,et al. Parkinson's disease and immunological abnormalities: increase of HLA‐DR expression on monocytes in cerebrospinal fluid and of CD45RO+ T cells in peripheral blood , 1994, Acta neurologica Scandinavica.
[80] T. Olsson,et al. γδ + T cells are increased in patients with Parkinson's disease , 1994, Journal of the Neurological Sciences.
[81] Tanner Cm,et al. Occupational and environmental causes of parkinsonism. , 1992, Occupational medicine.
[82] P. Mcgeer,et al. Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains , 1988, Neurology.
[83] I. T. Young. Proof without prejudice: use of the Kolmogorov-Smirnov test for the analysis of histograms from flow systems and other sources. , 1977, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[84] J. Streilein,et al. Immune Response to Immunization via the Anterior Chamber of the Eye , 1977, Journal of immunology.
[85] E. Masliah,et al. Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation. , 2007, The American journal of pathology.
[86] Vladimir N Uversky,et al. Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation. , 2007, Journal of neurochemistry.
[87] A. Sidhu,et al. An inflammatory pathomechanism for Parkinson's disease? , 2006, Current medicinal chemistry.
[88] Y. Lyubchenko,et al. Effects of nitration on the structure and aggregation of alpha-synuclein. , 2005, Brain research. Molecular brain research.
[89] E. Masliah,et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. , 2005, Neuron.
[90] Philippe Vernier,et al. Does alpha-synuclein modulate dopaminergic synaptic content and tone at the synapse? , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[91] Philippe Amouyel,et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. , 2004, Lancet.
[92] Min Zhu,et al. Lipid binding inhibits alpha-synuclein fibril formation. , 2003, The Journal of biological chemistry.
[93] V. Uversky,et al. Nitration inhibits fibrillation of human alpha-synuclein in vitro by formation of soluble oligomers. , 2003, FEBS letters.
[94] Pingping Guan,et al. MHCPred: bringing a quantitative dimension to the online prediction of MHC binding. , 2003, Applied bioinformatics.
[95] J. Trojanowski,et al. Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions. , 2002, The Journal of biological chemistry.
[96] J. Trojanowski,et al. Induction of alpha-synuclein aggregation by intracellular nitrative insult. , 2001, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[97] M. Hur,et al. Expression patterns of alpha-synuclein in human hematopoietic cells and in Drosophila at different developmental stages. , 2000, Molecules and cells.
[98] Alfred D. Eaton,et al. Oral tolerance. , 2000, American journal of respiratory and critical care medicine.
[99] R. Krüger,et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. , 1998, Nature genetics.
[100] M G Spillantini,et al. Alpha-synuclein in Lewy bodies. , 1997, Nature.
[101] S E Ide,et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. , 1997, Science.
[102] C. Tanner. Occupational and environmental causes of parkinsonism. , 1992, Occupational medicine.